Clinical Trials
Closed
Phase
Accrual
100%
Published
SWOG Clinical Trial Number
S0107
A Phase II Trial of Epothilone B Analogue BMS-247550 (NSC #710428) Every 21 Days in Patients With Advanced Pancreas Cancer
Research Committee(s)
Gastrointestinal Cancer
Activated
07-01-2001
Closed
06-01-2003
Closed
Phase
Accrual
81%
SWOG Clinical Trial Number
S0028
Protocol for Assessment of Gemcitabine and Paclitaxel for Metastatic Urothelial Cancer in Patients Aged 70 Years or Older (And in a Cohort of Patients Younger Than 60 Years)
Research Committee(s)
Genitourinary Cancer
Activated
07-01-2001
Closed
12-15-2006
Closed
Phase
Accrual
100%
Published
SWOG Clinical Trial Number
S0111
A Phase II Trial of Epothilone B Analogue BMS-247550 (NSC #710428) (IND 59699) Administered Every 21 Days in Patients with Hormone Refractory Prostate Cancer
Research Committee(s)
Genitourinary Cancer
Activated
06-15-2001
Closed
11-15-2003
Closed
Phase
Accrual
74%
Published
SWOG Clinical Trial Number
S0023
A Phase III Trial of Cisplatin/Etoposide/Radiotherapy with Consolidation Docetacel followed by Maintenance Therapy with ZD1839 (NSC-715055) or Placebo in Patients with Inoperable Locally Advanced Stage III Non-Small Cell Lung Cancer
Research Committee(s)
Lung Cancer
Activated
06-15-2001
Closed
04-15-2005
Closed
Phase
Accrual
100%
Published
SWOG Clinical Trial Number
S0012
A Comparative Randomized Study of Standard Doxorubicin And Cyclophosphamide Followed by Weekly Paclitaxel Vs. Weekly Doxorubicin And Daily Oral Cyclophosphamide Plus G-CSF Followed by Weekly Paclitaxel As Neoadjuvant Therapy For Inflammatory And Locally Advanced Breast Cancer
Research Committee(s)
Breast Cancer
Activated
05-01-2001
Closed
12-01-2005
Closed
Phase
Accrual
100%
Published
SWOG Clinical Trial Number
S0102
Docetaxel and Vinorelbine Plus Filgrastim for HER-2 Negative, Stage IV Breast Cancer, Phase II
Research Committee(s)
Breast Cancer
Activated
05-01-2001
Closed
01-01-2004
Closed
Phase
Accrual
100%
Published
SWOG Clinical Trial Number
S0109
A Phase II Study of Flavopiridol (NSC-649890) 1 Hour Bolus Days 1-3 Q 21 Days in Patients with Advanced Renal Cell Cancer
Research Committee(s)
Genitourinary Cancer
Activated
05-01-2001
Closed
02-01-2002
Closed
Phase
Accrual
87%
Published
SWOG Clinical Trial Number
S0108
Bevacizumab (rhuMAb) (NSC 704865) Therapy For Patients With Relapsed Aggressive Non-Hodgkin's Lymphoma
Research Committee(s)
Lymphoma
Activated
04-15-2001
Closed
12-01-2004
Closed
Phase
Accrual
100%
Published
SWOG Clinical Trial Number
S0101
A Phase II Study of Gemcitabine Plus Irinotecan (CPT-11) In Patients With Esophageal Cancer.
Research Committee(s)
Gastrointestinal Cancer
Activated
04-15-2001
Closed
02-01-2003
Closed
Phase
Accrual
33%
SWOG Clinical Trial Number
S0022
Phase II Trial of Concurrent Cisplatin/Docetaxel and Radiotherapy Followed by Consolidation Docetaxel in Stage IIIB Non-Small Cell Lung Cancer
Research Committee(s)
Lung Cancer
Activated
03-15-2001
Closed
02-01-2003
Closed
Phase
Accrual
100%
Published
SWOG Clinical Trial Number
S0009
Phase II Evaluation Of Neoadjuvant Chemotherapy, Interval Debulking Followed By Intraperitoneal Chemotherapy In Women With Stage III And IV Epithelial Ovarian Cancer, Fallopian Tube Cancer Or Primary Peritoneal Cancer
Research Committee(s)
Gynecologic Cancer
Activated
03-15-2001
Closed
02-01-2006
Closed
Phase
Accrual
100%
Published
SWOG Clinical Trial Number
S0016
A Phase III Trial of CHOP vs. CHOP + Rituximab vs. CHOP + Iodine-131-Labeled Monoclonal Anti-B1 Antibody (Tositumomab) For Treatment of Newly Diagnosed Follicular Non-Hodgkin's Lymphomas
Research Committee(s)
Lymphoma
Activated
03-01-2001
Closed
10-02-2008
Closed
Phase
Accrual
56%
Published
SWOG Clinical Trial Number
S0031
Evaluation of ZD 1839 (NSC #715055) for Advanced Transitional Cell Carcinoma of the Urothelium, Phase II
Research Committee(s)
Genitourinary Cancer
Activated
02-15-2001
Closed
10-15-2002
Closed
Phase
Accrual
100%
Published
SWOG Clinical Trial Number
S9915
A Phase II Study of PN401, 5-FU, and Leucovorin in Unresectable or Metastatic Adenocarcinoma of the Stomach.
Research Committee(s)
Gastrointestinal Cancer
Activated
02-15-2001
Closed
09-01-2002
Closed
Phase
Accrual
100%
Published
SWOG Clinical Trial Number
S0033
"Phase III Randomized, Intergroup Trial Assessing the Clinical Activity of STI-571 at Two Dose Levels in Patients with Unresectable or Metastatic Gastrointestinal Stromal Tumors (GIST) Expressing the KIT Receptor Tyrosine Kinase (CD117)"
Research Committee(s)
Sarcoma
Activated
12-15-2000
Closed
09-01-2001
Closed
Phase
Accrual
72%
Published
SWOG Clinical Trial Number
S0003
Randomized Phase III Trial of Carboplatin and Paclitaxel plus Tirapazamine versus Carboplatin and Paclitaxel in Patients with Advanced Non-Small Cell Lung Cancer - Cisplatin, Paclitaxel, Tirapazamine vs. Cisplatin, Paclitaxel - Specimen submission per S9925
Research Committee(s)
Lung Cancer
Activated
11-15-2000
Closed
11-15-2002
Closed
Phase
Accrual
100%
Published
SWOG Clinical Trial Number
S0007
Evaluation of 3 Hour Infusion of Paclitaxel Plus Cisplatin and 5-Fluorouracil in Patients with Advanced or Recurrent Squamous Cell Carcinoma of the Head and Neck (SCCHN)
Research Committee(s)
Head and Neck Cancer
Activated
11-01-2000
Closed
05-15-2003
Closed
Phase
Accrual
2%
Published
SWOG Clinical Trial Number
S0019
A Randomized Phase III Trial of ICE Chemotherapy With or Without Rituximab for the Treatment of Relapsed or Refractory CD20 Expressing Agressive B-Cell Non-Hodgkin's Lymphomas in Patients Not Suitable for High Dose Therapy and PBSCT.
Research Committee(s)
Lymphoma
Activated
10-15-2000
Closed
12-15-2001
Closed
Phase
Accrual
60%
Published
SWOG Clinical Trial Number
S0004
A Phase I Study of Tirapazamine/Cisplatin/Etoposide and Concurrent Thoracic Radiotherapy for Limited Stage Small Cell Lung Cancer
Research Committee(s)
Lung Cancer
Activated
10-15-2000
Closed
04-01-2002
Closed
Phase
Accrual
100%
Published
SWOG Clinical Trial Number
S9912
Phase II Evaluation of Intravenous Paclitaxel, Intraperitoneal Cisplatin, Intravenous Liposomal Doxorubicin and Intraperitoneal Paclitaxel in Women with Optimally-Debulked Stage III Epithelial Ovarian, Primary Peritoneal or Fallopian Tube Cancer
Research Committee(s)
Gynecologic Cancer
Activated
10-01-2000
Closed
08-15-2005